Is nattokinase good for seniors?

The one long-term trial built to answer this question enrolled 265 adults with a median age of 65.3 — and found nothing.

That null result sits awkwardly beside shorter trials showing modest blood pressure drops, and beside Japanese population data linking natto to lower cardiovascular mortality. Seniors have the most to gain: 71.6% of US adults aged 60 and over have hypertension [13]. They also have the most to lose, because bleeding risk climbs steeply with age.

Here is what the evidence supports after 65, and what it does not.

Table of Contents

1. Why Ageing Changes the Question
2. What Blood Pressure Trials Show — and Who Was in Them
3. The Three-Year Trial Seniors Should Know About
4. What Natto-Eating Populations Show — and Where the Analogy Breaks
5. The Bleeding Risk Seniors Need to Weigh
6. A Practical Framework for Deciding After 65
7. Why Formulation Details Matter More After 65
8. Frequently Asked Questions
9. Conclusion

1. Why Ageing Changes the Question

The reason nattokinase gets discussed for seniors specifically is that ageing tilts the clotting system in one direction. Plasma fibrinogen climbs with age, alongside several other coagulation factors [11], and that rise is not matched by an equivalent rise in the body's natural anticoagulants [10].

Clot breakdown moves the other way. Fibrinolytic activity is impaired in older adults [10], largely through rising plasminogen activator inhibitor-1 (PAI-1), the principal brake on the clot-dissolving system. A 2026 review of functional fibrinolysis in older adults [9] describes ageing as producing a hypofibrinolytic state — denser fibrin networks, smaller pore sizes, and longer clot lysis times.

That is a genuinely plausible mechanistic case, and it is the one nattokinase marketing leans on. But the same review is explicit that PAI-1 should currently be treated as a marker of biological ageing rather than a validated therapeutic target in geriatric practice [9]. Plausible mechanism and proven benefit are different things — a distinction that matters enormously once you are past 65 and the downside risks are real. If the mechanism itself is new to you, our guide to how nattokinase works covers the fibrinolytic pathway in detail.

2. What Blood Pressure Trials Show — and Who Was in Them

The most-cited human trial randomised 86 participants aged 20 to 80 with untreated systolic pressure between 130 and 159 mmHg [2] to 2,000 FU of nattokinase or placebo for 8 weeks. Systolic pressure fell 5.55 mmHg and diastolic 2.84 mmHg relative to control, with a drop in renin activity of 1.17 ng/mL/h. Seventy-three of the 86 completed.

A later meta-analysis pooling 6 randomised trials and 546 participants [3] found a smaller but consistent blood pressure effect: systolic down 3.45 mmHg, diastolic down 2.32 mmHg. The same analysis found less reassuring results on other measures — a small increase in blood glucose versus placebo, and unfavourable movement in total, HDL and LDL cholesterol at relatively low total doses. The authors framed nattokinase as a possible adjunct for hypertension rather than a treatment, and noted the lipid picture remains unresolved.

Two caveats matter for seniors. First, none of these trials was designed for people over 65 — the age ranges are broad and the older subgroups are small. Second, a 3 to 5 mmHg systolic reduction is meaningful at population scale but modest for an individual already on antihypertensive medication, and 51.2% of US adults with hypertension are already taking medication for it [13]. Our review of nattokinase and blood pressure breaks down each trial individually.

3. The Three-Year Trial Seniors Should Know About

This is the study most supplement content omits. The Nattokinase Atherothrombotic Prevention Study randomised 265 people with a median age of 65.3 and no clinical cardiovascular disease [1] to 2,000 FU of nattokinase or placebo, then tracked them with carotid ultrasound every 6 months for a median of 3 years.

After 3 years, the annualised rate of change in carotid intima-media thickness and carotid arterial stiffness did not differ between groups. Neither did blood pressure. Neither did any of the laboratory measures — coagulation factors, fibrinolysis markers, blood rheology, inflammatory markers, or metabolic factors. The authors concluded the effect was null in healthy individuals at low cardiovascular risk [1].

Read that conclusion precisely. The participants had no diagnosed cardiovascular disease and were low-risk at entry, so this trial does not prove nattokinase is useless in higher-risk older adults — it was not designed to test them. What it does show is that in the population most likely to buy it as general prevention, 3 years of the standard 2,000 FU dose changed nothing measurable. That is the single most relevant piece of evidence for a healthy 68-year-old considering it as insurance.

4. What Natto-Eating Populations Show — and Where the Analogy Breaks

The population data is more encouraging than the supplement trials. The Takayama Study followed 29,079 Japanese adults aged 35 and over for 16 years [7] and recorded 1,678 cardiovascular deaths. Those in the highest quartile of natto intake had a 25% lower risk of cardiovascular mortality than the lowest quartile.

A larger cohort reached similar conclusions. Following roughly 92,000 adults aged 45 to 74 [8], higher fermented soy intake was associated with about 10% lower all-cause mortality — hazard ratios of 0.90 in men and 0.89 in women comparing highest to lowest fifth — while total soy intake showed no association at all.

The gap between food and capsule is where this breaks down for seniors. Natto delivers vitamin K2, fibre, isoflavones and polyamines alongside the enzyme, and these are observational studies in which lifelong natto eaters differ from non-eaters in many unmeasured ways. Isolating one enzyme into a capsule does not carry the rest of the food with it. Those compositional differences are covered in our guide to natto as a whole food.

5. The Bleeding Risk Seniors Need to Weigh

The published harms cluster in exactly the demographic asking this question. A 2021 case report describes a 92-year-old woman with paroxysmal atrial fibrillation, chronic kidney disease and hypertension [4] who developed hemoperitoneum after taking over-the-counter nattokinase and died of the complications. An earlier report documented acute cerebellar hemorrhage after just 7 days of nattokinase 400 mg daily [5] in a patient on aspirin with pre-existing cerebral microbleeds.

These are case reports, not incidence rates, and the counterweight is real: an Italian observational study of 153 vascular surgery patients aged 22 to 92 [6] recorded symptom improvement with no adverse drug reactions or interactions. That study excluded anyone already taking an anticoagulant or antiplatelet drug, however — and trials routinely exclude the frail, the anticoagulated and the multi-morbid, which is to say they exclude the seniors most likely to be affected.

Memorial Sloan Kettering's clinical summary advises that nattokinase should not be used by people with ischemic stroke, peptic ulcer or coagulation disorders, those on anticoagulant therapy, or before and after surgery [12]. The same source notes a documented case of mechanical aortic valve thrombosis after a patient substituted nattokinase for warfarin. Specific risks worth naming:

• Additive antithrombotic effect: nattokinase's fibrinolytic and antiplatelet actions stack with warfarin, DOACs, aspirin and clopidogrel [12]
• No monitoring test: standard INR does not capture nattokinase activity, so the combined effect is invisible to routine bloodwork
• Surgical and dental risk: the National Institute on Aging warns that supplements can increase bleeding after injury and alter response to anesthesia [15]
• Disclosure gap: with 80.2% of women aged 60 and over using supplements [14], many prescribers are working from incomplete medication lists

Our full breakdown of nattokinase side effects and the detailed review of nattokinase as a natural blood thinner cover the interaction picture in more depth.

6. A Practical Framework for Deciding After 65

The honest answer to "is nattokinase good for seniors" is that it depends almost entirely on which senior. The National Institute on Aging's guidance [16] — understand what you are taking and why, and discuss it with your doctor first — is not boilerplate here. It is the whole decision.

Reasons to rule it out without further discussion:

• Taking any anticoagulant or antiplatelet, including low-dose aspirin, without explicit physician sign-off
• A mechanical heart valve — nattokinase is not a substitute for warfarin, and at least 1 published case ended in valve thrombosis [12]
• History of hemorrhagic or ischemic stroke, peptic ulcer, or any bleeding disorder [12]
• Any surgery or dental extraction scheduled — stop ahead of the procedure and tell the surgical team you were taking it

Where a conversation with a physician is reasonable: an adult over 60 not on antithrombotic medication, without bleeding history, with pre-hypertension or stage 1 hypertension already under medical supervision, who understands they are pursuing a 3 to 5 mmHg adjunct rather than a treatment. Dose matters here too — the trials used 2,000 FU daily, and our nattokinase dosage guide explains why FU activity, not milligrams, is the number to check on a label.

7. Why Formulation Details Matter More After 65

If a senior and their doctor do decide to proceed, two formulation details carry more weight in this age group than in any other.

The first is vitamin K2. Natto is naturally rich in it, and high K2 concentrations can reduce the INR in people taking warfarin [12] — an effect that can carry over into supplements where K2 is not removed during production. BioAbsorb's Nattokinase Enzyme is formulated free of vitamin K2, which removes that particular variable. It does not remove the underlying bleeding-risk question, and warfarin users still need physician sign-off before starting anything.

The second is dose verification. Each capsule delivers 100 mg standardised to 2,000 FU of fibrinolytic activity, third-party tested every batch for activity, heavy metals, gluten and microbial contaminants, in 60-capsule and 180-capsule sizes — the same 2,000 FU figure used in both the 8-week blood pressure trial [2] and the 3-year prevention study [1]. Delivery uses DRcaps delayed-release veggie capsules, which protect the enzyme from stomach acid without the phthalates and plasticizers found in conventional enteric coatings, taken as 1 capsule daily on an empty stomach.

Manufacturing is in a Canadian GMP-certified, non-irradiated facility, and the formula is non-GMO, 100% vegetarian, and free of gluten, nuts, eggs, dairy, fish and shellfish.

Frequently Asked Questions

Is there an age at which nattokinase becomes unsafe?

No specific age threshold has been established, and an observational study of patients not taking blood thinners included people up to 92 years old without recorded adverse drug reactions [6]. Risk tracks health status rather than birthday — anticoagulant use, kidney function, bleeding history and fall risk matter far more than the number itself.

Can I take nattokinase if I'm on warfarin or a DOAC like apixaban?

Not without your prescriber's explicit approval. Clinical summaries advise against combining nattokinase with concurrent anticoagulant therapy [12], and the fatal 2021 case involved an older adult with atrial fibrillation [4]. Standard INR testing does not measure nattokinase activity, so the combined effect cannot be monitored the usual way.

Does removing vitamin K2 make nattokinase safe with blood thinners?

No. Removing K2 eliminates one specific interaction — K2's ability to lower INR in warfarin users [12] — but the enzyme's own fibrinolytic and antiplatelet activity remains, and that is the additive bleeding concern. A K2-free formula changes one variable, not the underlying decision.

How long before surgery should a senior stop taking it?

Guidance advises avoiding nattokinase before and after surgery without specifying a universal interval [12]. Ask the surgical team directly and disclose the supplement — this applies to dental extractions and colonoscopies with biopsy, not just major operations.

Is eating natto better than taking a capsule?

For cardiovascular mortality, the strongest human evidence is for the food: a 25% lower risk in the highest natto-intake quartile [7] across 16 years. But natto is high in vitamin K2, which is a direct problem for warfarin users, and observational food data cannot be assumed to transfer to an isolated enzyme.

Will it let me reduce my blood pressure medication?

There is no evidence supporting that, and no trial has tested medication reduction as an outcome. The pooled effect is roughly 3.45 mmHg systolic [3] — never adjust prescribed antihypertensives without your physician.

Conclusion

For a healthy, low-risk senior, the best long-term evidence available is a 3-year trial in 265 adults with a median age of 65.3 that found no measurable benefit [1] — and the most severe published harms have occurred in exactly this age group. The reasonable position is neither enthusiasm nor dismissal, but a specific conversation with your physician about your own medications and bleeding risk. If that conversation leads somewhere, BioAbsorb's K2-free, third-party-tested Nattokinase Enzyme at 2,000 FU matches the dose used in the published research — and our complete guide to nattokinase is the place to start.

Research References

1. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78, Issue 4 (2021). Found no significant difference in carotid intima-media thickness, arterial stiffness, blood pressure or laboratory markers after a median 3 years of 2,000 FU nattokinase in 265 adults of median age 65.3 — the primary basis for this article's central caution.
2. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31, Issue 8 (2008). Reported net systolic and diastolic reductions of 5.55 and 2.84 mmHg over 8 weeks in 86 participants aged 20–80 with pre-hypertension or stage 1 hypertension.
3. Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Reviews in Cardiovascular Medicine, Vol. 24, Issue 8 (2023). Pooled 6 trials and 546 participants, finding systolic and diastolic reductions of 3.45 and 2.32 mmHg. Also reported a small increase in blood glucose versus placebo, and unfavourable changes in total, HDL and LDL cholesterol at relatively low total dosage.
4. Nattokinase-associated hemoperitoneum in an elderly woman. Cureus, Vol. 13, Issue 12 (2021). Case report of a 92-year-old with atrial fibrillation, chronic kidney disease and hypertension who developed fatal hemoperitoneum after over-the-counter nattokinase.
5. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Internal Medicine, Vol. 47, Issue 5 (2008). Documented acute cerebellar hemorrhage after 7 days of nattokinase 400 mg daily alongside aspirin in a patient with cerebral microangiopathy.
6. Data recorded in real life support the safety of nattokinase in patients with vascular diseases. Nutrients, Vol. 13, Issue 6 (2021). Observational study of 153 vascular patients aged 22–92 showing symptom improvement without adverse drug reactions or interactions; patients using anticoagulant or antiplatelet drugs were excluded.
7. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. American Journal of Clinical Nutrition, Vol. 105, Issue 2 (2017). Followed 29,079 adults for 16 years; highest natto quartile associated with 25% lower cardiovascular mortality (HR 0.75).
8. Association of soy and fermented soy product intake with total and cause specific mortality: prospective cohort study. BMJ, Vol. 368 (2020). Roughly 92,000 adults aged 45–74; fermented soy intake associated with about 10% lower all-cause mortality while total soy intake showed no association.
9. Functional fibrinolysis in older adults: clinical relevance and implications for personalised anticoagulation. GeroScience (2026). Narrative review describing age-related hypofibrinolysis and cautioning that PAI-1 remains a marker of biological ageing rather than a validated therapeutic target.
10. Hemostasis and ageing. Immunity & Ageing (2008). Summarised impaired fibrinolytic activity in older adults driven largely by rising plasminogen activator inhibitor-1, alongside age-related changes across the coagulation system.
11. GRSF1 antagonizes age-associated hypercoagulability via modulation of fibrinogen mRNA stability. Cell Death & Disease (2023). Reported that age-associated hypercoagulability is accompanied by rising plasma levels of coagulation factors including fibrinogen, and identified GRSF1 as a post-transcriptional regulator of fibrinogen expression.
12. Nattokinase. Memorial Sloan Kettering Cancer Center, Integrative Medicine herb monograph. Clinical summary of contraindications, anticoagulant interactions, vitamin K2 and INR effects, and the mechanical valve thrombosis case following warfarin substitution.
13. Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021–August 2023. National Center for Health Statistics, Data Brief No. 511 (2024). Source for 71.6% hypertension prevalence in adults aged 60 and over, and for 51.2% of adults with hypertension currently taking medication.
14. Dietary supplement use among adults: United States, 2017–2018. National Center for Health Statistics, Data Brief No. 399 (2021). Source for supplement use rates of 80.2% in women and 67.3% in men aged 60 and over.
15. Vitamins and minerals for older adults. National Institute on Aging. Warns that some supplements can increase the risk of bleeding after an injury or change response to anesthesia during surgery, and notes vitamin K's interference with warfarin.
16. Dietary supplements for older adults. National Institute on Aging. General guidance for older adults on understanding what a supplement is for, evaluating marketing claims, and discussing supplement use with a doctor before starting.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.